Antisense is the non-coding strand in double-stranded DNA. The antisense strand serves as the template for mRNA synthesis.
Isis Pharmaceuticals announced today that Eli Lilly and Company licensed LY2275796, a second-generation antisense anti-cancer drug candidate for clinical development.
As our understanding of biology increases, the tools of research become almost as important as the researchers wielding them. Currently, one of the major obstacles to research is actually getting inside of cells and tissue to see what is going on as it happens.
Using a new molecular genetic technique, scientists have turned procrastinating primates into workaholics by temporarily suppressing a gene in a brain circuit involved in reward learning. Without the gene, the monkeys lost their sense of balance between reward and the work required to get it, say researchers at the National Institute of Mental Health .
Poised on the brink of phenomenal growth, the oligonucleotides market offers a plethora of opportunities to the enterprising investor. Recent analysis by Frost & Sullivan estimates that the total global market for oligonucleotides is likely to grow from USD 340.0 million in 2003 to USD 776.0 million in 2010.
A team of researchers from the Universitat Autònoma de Barcelona (UAB) has discovered that transposons, small DNA sequences that travel through the genomes, can silence the genes adjacent to them by inducing a molecule called antisense RNA.
The idea is to use a modified form of HIV to deliver an "antisense" gene to the immune cells that HIV infects. This is integrated into the cells' genome, and stays there until a cell is infected. Then it is switched on, and produces RNA complementary to the "sense" RNA encoding a viral protein. In theory, the RNAs should bind together, blocking viral replication.
Targeting and inactivating a key gene could be a subtle and effective treatment for certain types of ovarian cancer, Scottish researchers suggest in a study published in Clinical Cancer Research.